type 2 diabetes mellitus
Conditions
Interventions
Patients are equipped with a Free Style Libre for 2 weeks from the start of study. 4 weeks after the start of study, patients are randomized to two groups. Group A: empagliflozin 10mg is added and
Sponsors
TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology
Division of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Out-patients with type 2 diabetes whose HbA1c are more than 6.5% and less than 15% and who have no changes of diabetic treatment (e.g. diet therapy, exercise cure, medication) within the past 8 weeks and who have been treated with linagliptin 5 mg and without SGLT2 inhibitors and sulfonyulureas.
Exclusion criteria
Exclusion criteria: 1. Patients who have renal dysfunction (eGFR is less than 30ml/min/1.73m2) 2. Pregnant women 3. Patients judged by the doctor to be ineligible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine albumin creatinine ratio, urin L-FABP. | — |
Secondary
| Measure | Time frame |
|---|---|
| Glycoalbumin, HbA1c, bodyweight, serum insurin, C-peptide, glucagon, eGFR. Blood glucose transition (standard deviation and MAGE), and average blood glucose level by a Free Style Libre. | — |
Countries
Japan
Contacts
Public ContactTakahiro Tosaki
TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology Diabetes and Endocrinology
Outcome results
None listed